Navigation Links
Nephros Signs Development Agreement with STERIS
Date:3/23/2010

RIVER EDGE, N.J., March 23 /PRNewswire-FirstCall/ -- Nephros, Inc. (OTC Bulletin Board: NEPH), a medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purification, today reported that is has entered into a development agreement with STERIS Corporation ( STE).

Under the terms of the agreement, Nephros and STERIS will jointly develop filtration-based products for medical device applications.  Nephros received an initial payment upon entering into the agreement and is eligible to receive additional payments upon successful completion of product development milestones.

"Nephros is investigating a range of commercial, industrial and retail opportunities for its DSU technology," said Ernest Elgin, President and CEO of Nephros.  "We are pleased to be working with STERIS to leverage our expertise in additional applications.  STERIS is a leader in the field of medical device sterilization, and we look forward to developing new products together to enhance patient safety."

In 2009, Nephros received 510(k) marketing approval from the FDA for the Dual Stage Ultrafilter (DSU) to be used to filter biological contaminants from water and bicarbonate concentrate used in hemodialysis procedures.  In August 2009, Nephros reported that it was awarded a new research contract from the U.S. Office of Naval Research ("ONR") for development of a portable dual-stage purifying filter.

About STERIS

The mission of STERIS Corporation is to provide a healthier today and safer tomorrow through knowledgeable people and innovative infection prevention, decontamination and health science technologies, products and services. The Company has approximately 5,000 dedicated employees around the world working together to supply a broad array of solutions by offering a combination of equipment, consumables and services to healthcare, pharmaceutical, industrial and government Customers. The Company is listed on the New York Stock Exchange under the symbol STE. For more information, visit www.steris.com.

About Nephros, Inc.

Nephros, Inc., headquartered in River Edge, New Jersey, is a medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purification.  The Nephros DSU is the basis for the Nephros line of water filtration products. The patented dual stage ultrafilter has the capability to filter out bacteria and, due to its exceptional filtration levels, filter out many viruses, parasites and biotoxins.

For more information about Nephros, please visit our website at http://www.nephros.com.

Forward-Looking Statements

Statements in this news release that are not historical facts constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "PSLRA"). Such statements may be preceded by words such as "may," "plans," "expects," "believes," "hopes," "potential" or similar words. For such statements, Nephros claims the protection of the PSLRA.

Forward-looking statements are not guarantees of future performance, are based on assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond Nephros' control. Actual results may differ materially from the expectations contained in the forward-looking statements. Factors that may cause such differences include the risks that Nephros may not be able: (i) to obtain additional funding when needed or on favorable terms; (ii) to continue as a going concern; (iii) to obtain appropriate or necessary governmental approvals to achieve its business plan or effectively market its products; (iv) to have its technologies and products accepted in current or future target markets; (v) to demonstrate in pre-clinical or clinical trials the anticipated efficacy, safety or cost savings of products that appeared promising to Nephros in research or clinical trials; or (vi) to secure or enforce adequate legal protection, including patent protection, for its products. More detailed information about Nephros and the risk factors that may affect the realization of forward-looking statements is set forth in Nephros' filings with the SEC, including Nephros' Annual Report on Form 10-K for the fiscal year ended December 31, 2008. Investors and security holders are encouraged to read these documents on the SEC's website at http://www.sec.gov/. Nephros does not undertake to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise except as required by law.

SOURCE Nephros, Inc.

Back to top

RELATED LINKS
http://www.nephros.com

'/>"/>

SOURCE Nephros, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Nephros Signs Canadian Distribution Agreement with Bellco Health Care Inc.
2. Nephros Reports 2009 Third Quarter Financial Results
3. Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltration Products
4. Water Street Healthcare Partners Signs Definitive Agreement to Sell Sierra Scientific Instruments to Given Imaging
5. MedeFile Signs Distribution Pact with Roadside Assist Giant NSD
6. San Diego Based CRO Signs Agreement With UK Based Spinal Device Manufacturer
7. Watson Signs Agreement to Divest Equity Interest in ScinoPharm
8. Pro Medicus/Visage Imaging Signs Deal with Sydney-based Southern Radiology
9. Amedica(R) Signs Joint Venture Agreement With Orthopaedic Synergy(R)
10. International Merchant Advisors, Inc. Signs LOI to Invest in Pharmaceutical Chain
11. Delcath Signs First Partner Agreement in Asia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... Wells Specialty Pharmacy announces the acquisitions and merger ... Winter Park, Florida and Pharm-EZ Medical, ... have been consolidated into the 3796 Howell Branch Road Facility. ... that Chad Tomlinson , former Vice President of Operations, ... Mr. Tomlinson is a Graduate of Florida State University and ...
(Date:1/19/2017)... 2017 Report Details What can ... are going to grow at the fastest rates? This ... data, trends, opportunities and prospects. Our 190-page report ... lucrative areas in the industry and the future market ... across the all the major categories of the ophthalmic ...
(Date:1/19/2017)... This report on the opioid induced constipation ... the global market. Large number of chronic pain sufferers ... is a major side effect of consumption of opioid ... therapy has been prescribed to treat opioid induced constipation. ... and growing awareness about the therapy are the major ...
Breaking Medicine Technology:
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... “Code Word: Chocolate Biscuit”: a biographical account ... Word: Chocolate Biscuit” is the creation of published author, Marlyn Ivey, born in Lynn Haven, ... he went to school and at 19 years of age, he joined the Navy and ...
(Date:1/20/2017)... ... January 20, 2017 , ... ... Oscillating Positive Expiratory Pressure (OPEP) device, was featured in a study indicating superior ... MEd, RRT-ACCS, FAARC, “Analysis of Three Oscillating Positive Expiratory Pressure Devices During ...
(Date:1/20/2017)... ... ... to Christmas:” a beautiful and enchanting tale that teaches children the true meaning of Christmas. ... in Oklahoma City, and a devoted woman of faith. , “Becoming a parent changes ... back of my mind for years, but actually doing it might have been a while ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... “The Land ... brings attention to the issue of world hunger, and shares the simple and achievable ... Brubaker, devoted husband and member of the Fairview Missionary Church in Angola, Indiana where ...
(Date:1/19/2017)... ... January 20, 2017 , ... Today, the Centers for Medicare & Medicaid ... CMS’s Alternative Payment Models (APMs) in 2017. Clinicians who participate in APMs are paid ... important part of the Administration’s effort to build a system that delivers better care ...
Breaking Medicine News(10 mins):